牛牛AI助手已提取核心信息
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 2,465 shares of common stock on February 28, 2024, according to a recent filing. The shares, valued at an aggregate market value of $26,129, were acquired by Watanabe on February 27, 2024, through the vesting of restricted stock directly from Arcutis Biotherapeutics. This transaction follows a period where no other sales were reported by Watanabe in the past three months.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 2,465 shares of common stock on February 28, 2024, according to a recent filing. The shares, valued at an aggregate market value of $26,129, were acquired by Watanabe on February 27, 2024, through the vesting of restricted stock directly from Arcutis Biotherapeutics. This transaction follows a period where no other sales were reported by Watanabe in the past three months.
根据最近的一份文件，Arcutis Biotherapeutics, Inc.高管托德·富兰克林·渡边定于2024年2月28日出售2465股普通股。这些股票的总市值为26,129美元，于2024年2月27日被渡边通过直接从Arcutis Biotherapeutics授予限制性股票的方式收购。这笔交易是在渡边在过去三个月中没有报告其他销售额之后进行的。
根据最近的一份文件，Arcutis Biotherapeutics, Inc.高管托德·富兰克林·渡边定于2024年2月28日出售2465股普通股。这些股票的总市值为26,129美元，于2024年2月27日被渡边通过直接从Arcutis Biotherapeutics授予限制性股票的方式收购。这笔交易是在渡边在过去三个月中没有报告其他销售额之后进行的。
有用
没用